TP53 and adrenal cortex carcinoma: At the molecular level, in addition to p53 and Wnt-β-catenin pathways for which no specific molecular target agents are currently in use, other potentially druggable pathways have been identified in ACC patients, such as the Epidermal Growth Factor Receptors (EGFRs), Insulin Growth Factor-Receptor 1 (IGF-1R), and Vascular Endothelial Growth Factor Receptors (VEGFRs).